(200 days)
Cholesterol 1,2,3TM is an in vitro diagnostic test for the quantification of skin cholesterol. Cholesterol 1,2,3TM uses a detector reagent that reacts with skin cholesterol in proportion to the amount of cholesterol on the surface of the epidermis. An indicator reagent (horseradish peroxidase substrate) is added and color allowed to develop. Color intensity is proportional to the amount of bound skin cholesterol in the palmar surface of the skin. The color intensity (hue) can be measured objectively by use of a handheld reflectance spectrophotometer.
Skin cholesterol as measured by Cholesterol 1,2,3TM can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being considered. Test results, when considered in conjunction with clinical evaluation, blood cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options.
The Cholesterol 1,2,3TM spectrophotometer in conjunction with the Cholesterol 1,2,3™ reagents are intended for use in the quantitative determination of cholesterol in the epidermal layer of the skin.
Here's a breakdown of the acceptance criteria and the study details for the Cholesterol 1,2,3™ device, based on the provided text:
Acceptance Criteria and Device Performance
The provided document does not explicitly state specific, quantifiable acceptance criteria (e.g., "sensitivity must be >X%", "accuracy must be >Y%"). Instead, it presents performance data in relation to the intended use. The closest indicators of "acceptance" are the statistical significance of skin cholesterol's contribution to risk and the ROC AUC for predicting multi-vessel CAD.
However, based on the Summary of Performance Data and the FDA's final decision, the implicit acceptance criteria appear to be centered around the device's ability to demonstrate:
- Correlation with Multi-Vessel Coronary Artery Disease (CAD): Show that increasing skin cholesterol levels correlate with an increased risk of significant multi-vessel CAD, especially in certain HDL ranges.
- Correlation with Prior Myocardial Infarction (MI): Show that increasing skin cholesterol levels correlate with an increased probability of prior MI, especially in certain HDL ranges.
- Lack of ability to rule out CAD: Acknowledge that the test cannot be used to rule out coronary artery disease.
- No correlation with HDL: Demonstrate that skin cholesterol measurements are independent of HDL levels.
- Precision/Reproducibility: Demonstrate reliable and consistent measurements.
- Safety and Effectiveness: Satisfy the FDA that the device is substantially equivalent to predicate devices for its specified indications for use, with appropriate limitations.
Here's a table summarizing the reported device performance against these implicit criteria:
| Acceptance Criteria (Implicit) | Reported Device Performance |
|---|---|
| 1. Correlation with Multi-Vessel CAD (Increased risk with higher skin cholesterol, especially in specific HDL ranges) | - Statistically Significant Contribution: Logistic regression analysis showed skin cholesterol had a statistically significant contribution (p=0.01) to the risk of significant multi-vessel CAD, even after adjusting for HDL.- ROC AUC: Area under receiver operating characteristics curve for skin cholesterol was 0.56 (95% CI: 0.52-0.61) for predicting significant multi-vessel CAD.- Observed Trends: Risk of significant multi-vessel CAD increased with skin cholesterol levels in subjects with HDL < 41 mg/dL. For HDL > 41 mg/dL, risk was highest in the middle skin cholesterol tertile. |
| 2. Correlation with Prior MI (Increased probability with higher skin cholesterol, especially in specific HDL ranges) | - Observed Trends: Probability of prior MI increased with skin cholesterol in individuals with low HDL levels. For HDL > 41 mg/dL, history of MI was lowest in the first skin cholesterol tertile and highest in the second tertile. |
| 3. Cannot be used to rule out CAD (Significant percentage of subjects in lowest skin cholesterol tertile still have CAD) | - Document explicitly states: "skin cholesterol level cannot be used to rule out coronary artery disease as even in the lowest skin cholesterol tertile significant percentages of subjects had coronary artery disease (only 26.9% of angiography subjects with skin cholesterol (<110) were without stenosis at three arteries)."- FDA warning: "The safety and effectiveness of this device for use in screening the general population for coronary artery disease... have not been established." |
| 4. No correlation between Skin Cholesterol and HDL | - Coefficient of Correlation: -0.06 (95% CI: -0.15; 0.02), indicating no correlation. |
| 5. Precision/Reproducibility (Consistent measurements) | - Within-Day CV: 11% (5-19%) for low SC, 7% (2-13%) for high SC.- Day-to-Day CV: 8% (4-17%) for low SC, 3% (1-5%) for high SC.- Batch-to-Batch CV: 10% (1-17%) for low SC (High SC not provided). |
| 6. Safety and Effectiveness (Substantial equivalence to predicates for "risk assessment" use without general screening) | - Determined by FDA to be substantially equivalent "for the indications for use stated in the enclosure" with the specific limitation in labeling regarding screening the general population for CAD and not being a substitute for blood tests. |
Study Information
2. Sample Size Used for the Test Set and Data Provenance:
- Sample Size: 750 individuals (649 patients scheduled for coronary angiography and 101 age and gender-matched controls).
- Data Provenance: The patients were "mostly Caucasian." The document does not specify the country of origin but implies a single study cohort. The study appears to be retrospective in nature, as it uses existing angiography data and history of MI to correlate with skin cholesterol measurements.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
- Ground Truth for CAD: "significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography)." The document does not specify the number or qualifications of experts (e.g., cardiologists, interventional radiologists) who performed or interpreted the coronary angiographies.
- Ground Truth for MI: "history of myocardial infarction (MI)." The source and qualification of those who established the history of MI are not specified.
4. Adjudication Method for the Test Set:
- The document does not specify an adjudication method for the coronary angiography results or the history of MI. It simply states that disease was "diagnosed by coronary angiography" or "history of MI."
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:
- No. This study is a standalone performance study of the device itself, correlating its measurements with clinical outcomes (CAD, MI). It does not involve human readers interpreting device outputs in a comparative effectiveness setting (AI vs. without AI assistance).
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:
- Yes. The study presents the performance of the Cholesterol 1,2,3™ device (spectrophotometer and reagents) in directly quantifying skin cholesterol and then correlating these quantitative measurements with clinical outcomes. There is no mention of a human-in-the-loop process for interpreting the "hue angle" measurement; it's a direct output of the device.
7. The Type of Ground Truth Used:
- Clinical Outcomes/Pathology (Angiography):
- Coronary Artery Disease: Significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography). Angiography is considered a clinical gold standard for assessing coronary stenosis.
- Myocardial Infarction: History of prior myocardial infarction. This is typically established through patient records, clinical diagnosis, and potentially previous diagnostic tests.
- Expert Consensus: Implied for the diagnosis from angiography/MI records, though not explicitly stated as an "expert consensus process" for this study.
8. The Sample Size for the Training Set:
- The document does not explicitly describe a separate training set for the device's development or the analysis presented. The 750 individuals appear to be the cohort used for the performance evaluation study. For the precision analysis, smaller groups (e.g., 20 candidates for within-day/day-to-day, 10 candidates for batch-to-batch) were used to validate the device's measurement consistency.
9. How the Ground Truth for the Training Set was Established:
- As no separate training set is detailed, information on how its ground truth was established is not provided. The ground truth for the evaluation was established as described in point 7.
{0}------------------------------------------------
JUN 2 4 2002
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3TM
Summary of Safety & Effectiveness Cholesterol 1,2,3TM
1.0 Submitted By:
Thomas M. Tsakeris Devices & Diagnostics Consulting Group, Inc. 16809 Briardale Road Rockville, MD 20855 Phone: 301-330-2076 Fax: 301-330-2568 E-mail: ttsak@erols.com
2.0 Date Submitted:
May 30, 2002
3.0 Device Name:
Cholesterol 1,2,3 TM
4.0 Predicate Devices:
| Predicate | Manufacturer | DocketNumber |
|---|---|---|
| Synchron CX® Systems HDL CholesterolReagent | Beckman Instruments, Inc. | K895851 |
| HDL Cholesterol Plus | Roche DiagnosticsCorporation | K000568 |
5.0 Description:
The Cholesterol 1,2,37M spectrophotometer in conjunction with the Cholesterol 1,2,3™ reagents are intended for use in the quantitative determination of cholesterol in the epidermal layer of the skin.
6.0 Intended Use and Indications for Use:
6.1 Intended Use:
Cholesterol 1,2,37% is an in vitro diagnostic test for the quantification of skin cholesterol. Cholesterol 1,2,3™ uses a detector reagent that reacts with skin cholesterol in proportion to the amount of cholesterol on the surface of the epidermis. An indicator reagent (horseradish peroxidase substrate) is added and color allowed to develop. Color intensity is proportional to the amount of bound skin cholesterol in the palmar surface of the skin. The color intensity (hue) can be measured objectively by use of a handheld reflectance spectrophotometer.
6.2 Indications for Use:
Skin cholesterol as measured by Cholesterol 1,2,37M can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being Test results, when considered in conjunction with clinical evaluation, blood considered. cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options.
{1}------------------------------------------------
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3 TM
7.0 Summary of Performance Data
Skin cholesterol levels were measured in 750 individuals (649 patients scheduled for coronary angiography and 101 age and gender matched controls). The patients were mostly Caucasian. For the 649 case patients who underwent coronary angiography, three coronary arteries (LAD, LCX and RCA) were scored as having no stenosis, up to 50% stenosis and greater than 50% stenosis.
As shown in Figure 1 and Table 1, the risk of significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel) increased as skin cholesterol levels increased in subjects with HDL levels less than 41 mg/dL. In subjects with HDL levels greater than 41 mg/dL the risk of multi-vessel disease was highest in the middle skin cholesterol tertile. The prevalence of significant multi-vessel coronary artery disease for angiography patients in this study was 36.5% (237/649).
Figure 1. Relative Risks of Significant Multi-Vessel Coronary Artery Disease (>50% stenosis in >1 vessel} According to Skin Cholesterol Tertile and HDL Range (the risk of significant multivessel coronary artery disease for subjects with HDL <41 is considered as one). Units of measure for skin cholesterol and HDL are hue angle (h') and mg/dL respectively.
Image /page/1/Figure/5 description: The image is a line graph that shows the relative risk of skin cholesterol tertile. The x-axis represents the skin cholesterol tertile, with values of 1 (<110), 2 (110-135), and 3 (>135). The y-axis represents the relative risk, ranging from 0 to 1.4. There are three lines on the graph, representing HDL >50, HDL 41-50, and HDL <41.
{2}------------------------------------------------
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3TM
Table 1. Data presented in Figure 1 are shown in this table. Data are presented as average relative risks of significant multi-vessel disease with 95% confidence intervals and ratios of number of patients with significant multi-vessel disease to total number (the risk of significant multi-vessel coronary artery disease for subjects with HDL<41 is considered as one).
| Skin Cholesterol (SC) Level (hue angle) | ||||
|---|---|---|---|---|
| HDL Level(mg/dL) | <110 | 110-135 | >135 | Average RelativeRisk forHDL Group |
| >50 | 0.53(0.29; 0.85)(12/56) | 0.78(0.48; 1.12)(17/54) | 0.58(0.27; 1.01)(8/34) | 0.63(0.47; 0.83)(37/144) |
| 41-50 | 0.67(0.40; 1.01)(15/55) | 1.15(0.78; 1.53)(21/45) | 0.99(0.67; 1.33)(22/55) | 0.92(0.74; 1.12)(58/155) |
| <41 | 0.83(0.62; 1.07)(37/109) | 1.04(0.82; 1.28)(50/118) | 1.10(0.88; 1.33)(55/123) | 1(142/350) |
| AverageRelative Riskfor SC Group | 0.72(0.57; 0.88)(64/220) | 1.00(0.84; 1.17)(88/217) | 0.99(0.83; 1.16)(85/212) |
The logistic regression analysis of skin cholesterol and HDL levels as risks factors for significant multi-vessel coronary artery disease showed that the skin cholesterol had statistically significant contribution (p=0.01) to the risk of significant multi-vessel disease even after adjusting for HDL cholesterol. The area under receiver operating characteristics curve for the skin cholesterol was 0.56 with 95% confidence interval of 0.52-0.61.
Figure 2 and Table 2 show that the probability to have prior myocardial infarction (MI) increased as skin cholesterol in individuals with low HDL levels. In subjects with HDL levels >41 mg/dL, history of MI was lowest in the first skin cholesterol tertile and highest in second tertile. The prevalence of history of MI for angiography patients in this study was 34.7% (225/649).
{3}------------------------------------------------
Figure 2. Relative Risks of Prior Myocardial Infarction (MI) According to Skin Cholesterol tertile and HDL range (the risk of prior MI for subjects with HDL<41 is considered as one). Units of measure for skin cholesterol and HDL are hue angle (hº) and mg/dL respectively.
Image /page/3/Figure/2 description: The image is a graph that shows the relative risk of different levels of HDL cholesterol. The x-axis is the skin cholesterol tertile, and the y-axis is the relative risk. There are three lines on the graph, representing HDL >50, HDL 41-50, and HDL <41. The graph shows that the relative risk of HDL >50 is lower than the relative risk of HDL 41-50 and HDL <41.
Table 2. Data presented in Figure 2 are shown in this table. Data are presented as average relative risks of prior MI with 95% confidence intervals and ratios of number of patients with prior MI to total number (the risk of prior MI for subjects with HDL < 41 is considered as one).
| Skin Cholesterol (SC) Level (hue angle) | ||||
|---|---|---|---|---|
| HDL Level(mg/dL) | <110 | 110-135 | >135 | Average Risk forHDL Group |
| >50 | 0.24(0.09; 0.49)(6/56) | 0.62(0.37; 0.93)(15/54) | 0.39(0.15; 0.78)(6/34) | 0.42(0.28; 0.59)(27/144) |
| 41-50 | 0.45(0.23; 0.74)(11/55) | 0.80(0.49; 1.15)(16/45) | 0.61(0.36; 0.92)(15/55) | 0.61(0.46; 0.78)(42/155) |
| <41 | 0.82(0.62; 1.07)(40/109) | 1.04(0.78; 1.20)(52/118) | 1.17(0.96; 1.37)(64/123) | 1(156/350) |
| Average Riskfor SC Group | 0.58(0.46; 0.72)(57/220) | 0.91(0.71; 1.01)(83/217) | 0.90(0.75; 1.05)(85/212) |
Figure 3 and Table 3 show that the angiography patients with low skin cholesterol (<110) and high HDL (>50 mg/dL) had the highest probability of being without disease (no stenosis at any three arteries). Conversely, the patients with high skin cholesterol (>135) and low HDL (<41 mg/dL) had the lowest probability of being without disease. However, skin cholesterol level cannot be used to rule out coronary artery disease as even in the lowest skin cholesterol tertile significant percentages of subjects had coronary artery disease (only 26.9% of angiography subjects with skin cholesterol (<110) were without stenosis at three arteries). The skin cholesterol test cannot be used to screen the general population for no CAD. The
{4}------------------------------------------------
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3TM
prior probability (prevalence) of no disease for angiography patients in this study was 23.6% (153/649).
Figure 3. Probability of No Coronary Artery Disease According to Skin Cholesterol Tertile and HDL Range. Units of measure for skin cholesterol and HDL are hue angle (h') and mg/dL respectively.
Image /page/4/Figure/3 description: The figure is a line graph that shows the relationship between skin cholesterol tertile and the percent without significant disease, broken down by HDL levels. The x-axis represents skin cholesterol tertile, with values of 1 (<110), 2 (110-135), and 3 (>135). The y-axis represents the percent without significant disease, ranging from 0 to 50. The graph shows three lines representing HDL levels: HDL >50, HDL 41-50, and HDL <41.
Table 3. Data presented in Figure 3 are shown in this table. Data are presented as average percent without coronary artery disease (no stenosis at any three arteries) with 95% confidence intervals.
| Skin Cholesterol (SC) Level (hue angle) | ||||||
|---|---|---|---|---|---|---|
| HDL Level(mg/dL) | <110 | 110-135 | >135 | Average Risk forHDL Group | ||
| >50 | 37.5%(21/56)(24.9%; 51.5%) | 38.9%(21/54)(25.9%; 53.1%) | 44.1%(15/34)(27.2%; 62.1%) | 39.6%(57/144)(31.5%; 48.1%) | ||
| 41-50 | 30.9%(17/55)(19.1%; 44.8%) | 20.0%(9/45)(9.6%; 34.6%) | 21.8%(12/55)(11.8%; 35.0%) | 24.5%(38/155)(18.0%; 32.1%) | ||
| <41 | 19.3%(21/109)(12.3%; 27.9%) | 20.3%(24/118)(13.5%; 28.7%) | ||||
| Average Riskfor SC Group | 26.9%(59/220)(21.1%; 33.2%) | 24.9%(54/217)(19.3%; 31.2%) | 18.9%(40/212)(13.8%; 24.8%) |
{5}------------------------------------------------
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3 M
As shown in table 4, data of this study demonstrated that there is no correlation of skin cholesterol with HDL (coefficient of correlation = - 0.06 with 95% confidence interval (-0.15; 0.02)).
| Skin Cholesterol (SC) Level (hue angle) | ||||
|---|---|---|---|---|
| HDLLevel(mg/dL) | <110 | 110-135 | >135 | |
| >50 | 8.6%56 | 8.3%54 | 5.2%34 | 22.2%144 |
| 41-50 | 8.5%55 | 6.9%45 | 8.5%55 | 23.9%155 |
| <41 | 16.8%109 | 18.2%118 | 19.0%123 | 53.9%350 |
| 33.9%220 | 33.4%217 | 32.7%212 | 100%649 |
Table 4. Distribution of Skin Cholesterol Levels and HDL Concentration.
8.0 Specific Performance Characteristics
8.1 Precision
Table 1 shows the reproducibility of Cholesterol 1,2,300 within-day, between days, and from batch to batch.
| Table 1. Reproducibility of Cholesterol 1,2,3 "M: Mean CV (range) | |||||
|---|---|---|---|---|---|
| ------------------------------------------------------------------- | -- | -- | -- | -- | -- |
| Within-Day | Day-to-Day | Batch-to-Batcha | |
|---|---|---|---|
| Low skin cholesterol | 11% (5-19%) | 8% (4-17%) | 10% (1-17%) |
| High skin cholesterol | 7% (2-13%) | 3% (1-5%) |
4 3 lots of Cholesterol 1,2,310 were compared
For within day variability, three replicate Cholesterol 1,2,37M tests were carried out on the palmar surface of each hand on twenty candidates (10 individuals in each of the low and high skin cholesterol ranges) with a single lot of Cholesterol 1,2,3™. Three different areas of the palm were used. For day-to-day variability, a single Cholesterol 1,2,37M test was carried out on twenty candidates (10 individuals in each of the low and high skin cholesterol ranges) for 5 consecutive days. A single lot of Cholesterol 1,2,37M was used. For between lot variability, ten candidates were tested with three different Cholesterol 1,2,3™ kit lots. All three tests for each individual were performed on the same day on three different areas of the palm.
{6}------------------------------------------------
IMI - International Medical Innovations Inc., Section 510(k) Notification Cholesterol 1,2,3TM
8.2 Skin Cholesterol Values in Healthy Subjects
Table 6 shows the levels of skin cholesterol in the control Caucasian and African-American populations. The mean skin cholesterol values for these healthy subjects are within the lowest tertile of the angiographic subjects (<110).
| Caucasians* | African Americans** | |
|---|---|---|
| N | 101 | 94 |
| Mean | 105.0 | 88.7 |
| 2.5 percentile | 66 | 62 |
| 97.5 percentile | 169 | 131 |
Table 6. Expected Skin Cholesterol Values in Control Subjects
- mean age: 61 (40-82), 41% female ** mean age 42 (19-70), 79% female
Figure 4 shows the distribution of skin cholesterol for the control population by race.
Image /page/6/Figure/7 description: This bar graph compares the skin cholesterol hue angle of Caucasian and African American subjects. The x-axis represents the skin cholesterol hue angle, divided into categories such as "<75", "76-85", "86-95", "96-105", "106-115", "116-125", "126-135", "136-145", and ">145". The y-axis represents the number of subjects. For example, in the 86-95 range, there are approximately 21 Caucasian subjects and 25 African American subjects.
Figure 4. Distribution of Skin Cholesterol by Race
This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.
{7}------------------------------------------------
Image /page/7/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.
JUN 2 4 2002
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
International Medical Innovation, Inc. c/o Thomas M. Tsakeris President Devices & Diagnostics Consulting Group, Inc. 16809 Briardale Road Rockville, MD 20855
Re: K014018
Trade/Device Name: Cholesterol 1,2,3™ Regulation Number: 21 CFR 862.1475 Regulation Name: Lipoprotein test system Regulatory Class: I, reserved Product Code: LBS Dated: May 31, 2002 Received: May 31, 2002
Dear Mr. Tsakeris:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in screening the general population for coronary artery disease or for use as a substitute for blood cholesterol tests or a substitute for other risk factors identified for coronary artery disease have not been established.
{8}------------------------------------------------
Page 2 - Mr. Thomas M. Tsakeris
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement above is added to your labeling, as described.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Bernard E. Statland, M.D., Ph.D. Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{9}------------------------------------------------
510(k) Number (if known): K014018
Device Name: Cholesterol 1,2,3TM
Intended Use Statement
Cholesterol 1,2,37M is an in vitro diagnostic test for the quantification of skin cholesterol. Cholesterol 1.2.37M uses a detector reagent that reacts with skin cholesterol in proportion to the amount of cholesterol on the surface of the epidermis. An indicator reagent (horseradish peroxidase substrate) is added and color allowed to develop. Color intensity is proportional to the amount of bound skin cholesterol in the palmar surface of the skin. The color intensity (hue) can be measured objectively by use of a handheld reflectance spectrophotometer.
Indications For Use Statement
Skin cholesterol as measured by Cholesterol 1,2,37M can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being considered. Test results, when considered in conjunction with clinical evaluation, blood cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options.
(Division Sign-Off) Division of Clinical Laboratory Devices
510(k) Number: K014018
For Prescription Use V (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
A. Butner
6124/02
(Division Sign-Off) Division of Clinical Laboratory Devices K 2000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 510(k) Number.
§ 862.1475 Lipoprotein test system.
(a)
Identification. A lipoprotein test system is a device intended to measure lipoprotein in serum and plasma. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.